Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.French company MAT Biopharma has initiated an escalating-dose phase I/II study of its antibody Ferritarg P in patients with relapsed or refractory Hodgkin's disease.
Subscribe to our email newsletter
The study conducted in collaboration with Institut Curie will seek to enroll around 20 patients.
The goal of this study is to evaluate pharmacokinetic, the safety and the maximum tolerated dose of Ferritarg P in patients with Hodgkin's disease. In July 2006, FDA granted orphan drug designation to Ferritarg P. Hodgkin's disease, also known as Hodgkin's lymphoma, is a rare cancer of the lymphatic system.
“The initiation of this trial is an important milestone in the development of Ferritarg P and has the potential to be a significant driver of the company's future growth,” said Jean Kadouche, CEO.